Senior Research Fellow
Dr Richard Hill joined us from Portugal at the beginning of August 2015. Dr Hill obtained a BSc degree in Genetics from the University of Leicester (1999) and completed a PhD degree (with distinction) in Molecular Oncology from Imperial College London with a Cancer Research UK scholarship (2004). He continued his scientific career as a postdoctoral fellow in Dalhousie University in Canada (January 2005-2012) and during this time was funded by a Cancer Research Training Fellowship and a separate PDF award from the Terry Fox Foundation. He moved to Portugal in 2012 to start his laboratory where he was funded by an FCT fellowship. Dr Hill has published 25 peer reviewed manuscripts and his Research Gate Score is 30.21 and his H-index currently stands at 16. He has given talks at various international meetings, including the American Association of Cancer Research, the American Association of Gene Therapy, Canadian Institute for Health Research (CIHR), Terry Fox Foundation and the European Association of Cancer Research. His major achievements to date are the development of mouse models for the preclinical testing of oncolytic therapies, understanding how DNA-PK regulates p53-mediated apoptosis, revealing that DNA-PK can modulate transcription, the role of PI3KK’s following KSHV (viral) infection, the identification of a new melanoma biomarker that directly impacts the clinical outcome for cancer patients and screening novel therapeutics for the treatment of cancer. Since arriving at Portsmouth Dr Hill has facilitated a series of investigations on screening novel and repurposed/re-formulated agents both singularly and in combination against adult and paediatric primary and secondary brain tumours. He is utilising both 2D and 3D culture systems of biopsy-derived cells to assess autophagy and apoptosis in drug treated brain tumour cell populations.